n/a
Article Publish Status: FREE
Abstract Title:

A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Curcumin (Boswellia (), and French Maritime Pine Bark ().

Abstract Source:

Int J Environ Res Public Health. 2021 03 3 ;18(5). Epub 2021 Mar 3. PMID: 33802272

Abstract Author(s):

Emily K Donovan, Sophia Kekes-Szabo, Joanne C Lin, Rebecca L Massey, James D Cobb, Kathleen S Hodgin, Timothy J Ness, Carl Hangee-Bauer, Jarred W Younger

Article Affiliation:

Emily K Donovan

Abstract:

This report is part of a larger study designed to rapidly and efficiently screen potential treatments for Gulf War Illness (GWI) by testing nine different botanicals. In this placebo-controlled, pseudo-randomized, crossover clinical trial of 20 men with GWI, we tested three botanical agents with putative peripheral and central anti-inflammatory actions: curcumin (), boswellia (), and French maritime pine bark extract (). Participants completed 30 +/- 3 days of baseline symptom reports, followed by 30 +/- 3 days of placebo, 30 +/- 3 days of lower-dose botanical, and 30 +/- 3 days of higher-dose botanical. Participants then repeated the process with a new botanical until completing up to three botanical cycles. Data were analyzed using linear mixed models. Curcumin reduced GWI symptom severity significantly more than placebo at both the lower (<0.0001) and higher (= 0.0003) dosages. Boswellia was not more effective than placebo at reducing GWI symptoms at either the lower (= 0.726) or higher (= 0.869) dosages. Maritime pine was not more effective than placebo at the lower dosage (= 0.954) but was more effective than placebo at the higher dosage (= 0.006). This study provides preliminary evidence that curcumin and maritime pine may help alleviate symptoms of GWI. As a screening study, a final determination of the efficacy of these compounds for all individuals with GWI cannot be made, and further studies will need to be conducted to determine strength and durability of effects, as well as optimal dosage. These results suggest that GWI may, at least in part, involve systemic inflammatory processes. This trial was registered on ClinicalTrials.gov (NCT02909686) on 13 September 2016.

Study Type : Human Study

Print Options


Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & receive The Dark Side of Wheat Ebook

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

The Dark Side of Wheat

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2023 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.